Literature DB >> 18179901

X-linked dominant scapuloperoneal myopathy is due to a mutation in the gene encoding four-and-a-half-LIM protein 1.

Catarina M Quinzii1, Tuan H Vu, K Christopher Min, Kurenai Tanji, Sandra Barral, Raji P Grewal, Andrea Kattah, Pilir Camaño, David Otaegui, Teruhito Kunimatsu, David M Blake, Kirk C Wilhelmsen, Lewis P Rowland, Arthur P Hays, Eduardo Bonilla, Michio Hirano.   

Abstract

Scapuloperoneal (SP) syndrome encompasses heterogeneous neuromuscular disorders characterized by weakness in the shoulder-girdle and peroneal muscles. In a large Italian-American pedigree with dominant SP myopathy (SPM) previously linked to chromosome 12q, we have mapped the disease to Xq26, and, in all of the affected individuals, we identified a missense change (c.365G-->C) in the FHL1 gene encoding four-and-a-half-LIM protein 1 (FHL1). The mutation substitutes a serine for a conserved trypophan at amino acid 122 in the second LIM domain of the protein. Western blot analyses of muscle extracts revealed FHL1 loss that paralleled disease severity. FHL1 and an isoform, FHL1C, are highly expressed in skeletal muscle and may contribute to stability of sarcomeres and sarcolemma, myofibrillary assembly, and transcriptional regulation. This is the first report, to our knowledge, of X-linked dominant SP myopathy and the first human mutation in FHL1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18179901      PMCID: PMC2253963          DOI: 10.1016/j.ajhg.2007.09.013

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  24 in total

1.  Characterization of two isoforms of the skeletal muscle LIM protein 1, SLIM1. Localization of SLIM1 at focal adhesions and the isoform slimmer in the nucleus of myoblasts and cytoplasm of myotubes suggests distinct roles in the cytoskeleton and in nuclear-cytoplasmic communication.

Authors:  S Brown; M J McGrath; L M Ooms; R Gurung; M M Maimone; C A Mitchell
Journal:  J Biol Chem       Date:  1999-09-17       Impact factor: 5.157

2.  [On the nosological role of the scapulo-peroneal syndrome].

Authors:  I HAUSMANOWA-PETRUSEWICZ; S ZIELINSKA
Journal:  Dtsch Z Nervenheilkd       Date:  1962

Review 3.  The LIM domain: from the cytoskeleton to the nucleus.

Authors:  Julie L Kadrmas; Mary C Beckerle
Journal:  Nat Rev Mol Cell Biol       Date:  2004-11       Impact factor: 94.444

Review 4.  The multifunctional roles of the four-and-a-half-LIM only protein FHL2.

Authors:  M Johannessen; S Møller; T Hansen; U Moens; M Van Ghelue
Journal:  Cell Mol Life Sci       Date:  2006-02       Impact factor: 9.261

5.  Four and a half LIM protein 1 binds myosin-binding protein C and regulates myosin filament formation and sarcomere assembly.

Authors:  Meagan J McGrath; Denny L Cottle; Mai-Anh Nguyen; Jennifer M Dyson; Imogen D Coghill; Paul A Robinson; Melissa Holdsworth; Belinda S Cowling; Edna C Hardeman; Christina A Mitchell; Susan Brown
Journal:  J Biol Chem       Date:  2006-01-09       Impact factor: 5.157

6.  Chromosomal mapping, tissue distribution and cDNA sequence of four-and-a-half LIM domain protein 1 (FHL1).

Authors:  S M Lee; S K Tsui; K K Chan; M Garcia-Barcelo; M M Waye; K P Fung; C C Liew; C Y Lee
Journal:  Gene       Date:  1998-08-17       Impact factor: 3.688

7.  Scapuloperoneal syndrome type Kaeser and a wide phenotypic spectrum of adult-onset, dominant myopathies are associated with the desmin mutation R350P.

Authors:  M C Walter; P Reilich; A Huebner; D Fischer; R Schröder; M Vorgerd; W Kress; C Born; B G Schoser; K H Krause; U Klutzny; S Bulst; J R Frey; H Lochmüller
Journal:  Brain       Date:  2007-04-17       Impact factor: 13.501

8.  Characterization of a brain-specific nuclear LIM domain protein (FHL1B) which is an alternatively spliced variant of FHL1.

Authors:  S M Lee; H Y Li; E K Ng; S M Or; K K Chan; M Kotaka; S S Chim; S K Tsui; M M Waye; K P Fung; C Y Lee
Journal:  Gene       Date:  1999-09-03       Impact factor: 3.688

9.  The LIM proteins FHL1 and FHL3 are expressed differently in skeletal muscle.

Authors:  M J Morgan; A J Madgwick
Journal:  Biochem Biophys Res Commun       Date:  1999-02-16       Impact factor: 3.575

10.  MYH7 gene mutation in myosin storage myopathy and scapulo-peroneal myopathy.

Authors:  Elena Pegoraro; Bruno F Gavassini; Carlo Borsato; Paola Melacini; Andrea Vianello; Roberto Stramare; Giovanna Cenacchi; Corrado Angelini
Journal:  Neuromuscul Disord       Date:  2007-03-02       Impact factor: 4.296

View more
  44 in total

Review 1.  Myofibrillar myopathies: new developments.

Authors:  Montse Olivé; Rudolf A Kley; Lev G Goldfarb
Journal:  Curr Opin Neurol       Date:  2013-10       Impact factor: 5.710

2.  An analysis of exome sequencing for diagnostic testing of the genes associated with muscle disease and spastic paraplegia.

Authors:  Cristina Dias; Murat Sincan; Praveen F Cherukuri; Rosemarie Rupps; Yan Huang; Hannah Briemberg; Kathryn Selby; James C Mullikin; Thomas C Markello; David R Adams; William A Gahl; Cornelius F Boerkoel
Journal:  Hum Mutat       Date:  2012-02-28       Impact factor: 4.878

3.  Identification of two novel SMCHD1 sequence variants in families with FSHD-like muscular dystrophy.

Authors:  Jincy Winston; Laura Duerden; Matthew Mort; Ian M Frayling; Mark T Rogers; Meena Upadhyaya
Journal:  Eur J Hum Genet       Date:  2014-04-23       Impact factor: 4.246

4.  Fhl1 as a downstream target of Wnt signaling to promote myogenesis of C2C12 cells.

Authors:  Jing-Yu Lee; I-Chun Chien; Win-Yu Lin; Shao-Min Wu; Bo-Huei Wei; Yu-En Lee; Hu-Hui Lee
Journal:  Mol Cell Biochem       Date:  2012-02-26       Impact factor: 3.396

5.  Patients with a phenotype consistent with facioscapulohumeral muscular dystrophy display genetic and epigenetic heterogeneity.

Authors:  Sabrina Sacconi; Pilar Camaño; Jessica C de Greef; Richard J L F Lemmers; Leonardo Salviati; Pascal Boileau; Adolfo Lopez de Munain Arregui; Silvère M van der Maarel; Claude Desnuelle
Journal:  J Med Genet       Date:  2011-10-07       Impact factor: 6.318

6.  Dysregulation of FHL1 spliceforms due to an indel mutation produces an Emery-Dreifuss muscular dystrophy plus phenotype.

Authors:  Heather R Tiffin; Zandra A Jenkins; Mary J Gray; Sophia R Cameron-Christie; Jennifer Eaton; Salim Aftimos; David Markie; Stephen P Robertson
Journal:  Neurogenetics       Date:  2013-03-02       Impact factor: 2.660

7.  Clinical, histological and genetic characterization of reducing body myopathy caused by mutations in FHL1.

Authors:  Joachim Schessl; Ana L Taratuto; Caroline Sewry; Roberta Battini; Steven S Chin; Baijayanta Maiti; Alberto L Dubrovsky; Marcela G Erro; Graciela Espada; Monica Robertella; Maria Saccoliti; Patricia Olmos; Leslie R Bridges; Peter Standring; Ying Hu; Yaqun Zou; Kathryn J Swoboda; Mena Scavina; Hans-Hilmar Goebel; Christina A Mitchell; Kevin M Flanigan; Francesco Muntoni; Carsten G Bönnemann
Journal:  Brain       Date:  2009-01-29       Impact factor: 13.501

8.  Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy.

Authors:  Lucie Gueneau; Anne T Bertrand; Jean-Philippe Jais; Mustafa A Salih; Tanya Stojkovic; Manfred Wehnert; Maria Hoeltzenbein; Simone Spuler; Shinji Saitoh; Annie Verschueren; Christine Tranchant; Maud Beuvin; Emmanuelle Lacene; Norma B Romero; Simon Heath; Diana Zelenika; Thomas Voit; Bruno Eymard; Rabah Ben Yaou; Gisèle Bonne
Journal:  Am J Hum Genet       Date:  2009-08-27       Impact factor: 11.025

9.  Maintenance of muscle mass, fiber size, and contractile function in mice lacking the Z-disc protein myotilin.

Authors:  Julien Ochala; Olli Carpén; Lars Larsson
Journal:  Ups J Med Sci       Date:  2009       Impact factor: 2.384

10.  Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy.

Authors:  Belinda S Cowling; Meagan J McGrath; Mai-Anh Nguyen; Denny L Cottle; Anthony J Kee; Susan Brown; Joachim Schessl; Yaqun Zou; Josephine Joya; Carsten G Bönnemann; Edna C Hardeman; Christina A Mitchell
Journal:  J Cell Biol       Date:  2008-12-15       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.